Reimbursed Care Access in Norfolk Island

Since 1 July 2023 the Therapeutic Goods Administration amended the Poisons Standard to allow psilocybin to be used as a Schedule 8 (Controlled Drug) medicine for the specifically‑defined indication of treatment‑resistant depression (TRD). Under the TGA changes, access is limited to psychiatrists who have obtained Human Research Ethics Committee (HREC) approval and individual authorisation under the TGA Authorised Prescriber scheme, and psilocybin must be administered in a controlled medical setting in combination with psychotherapy; for all other uses psilocybin remains Schedule 9 (prohibited) and is restricted to approved research. The TGA has explicitly warned that because of strict safeguards, psychiatrists and supply chains may take time to be established and that there are strict importation and supply controls. # #

Reimbursement/access notes: The TGA’s scheduling change authorises clinical prescribing under strict conditions but does not, by itself, place psilocybin products on the Pharmaceutical Benefits Scheme (PBS). At the time of the TGA decision there were no TGA‑approved commercial products containing psilocybin; availability therefore depends on authorised psychiatrists obtaining authorised (often unapproved) product supply pathways and any state/territory controlled‑drugs approvals. Consequently, routine public reimbursement through PBS/Medicare for psilocybin‑assisted therapy has not been established as a general entitlement; treatments to date have been delivered by authorised specialist programs or in clinical trials and would generally involve substantial out‑of‑pocket costs unless a specific public program or PBS listing is later enacted. #

The Therapeutic Goods Administration amended the Poisons Standard effective 1 July 2023 to permit MDMA (3,4‑methylenedioxy‑methamphetamine) to be prescribed as a Schedule 8 medicine only for the treatment of post‑traumatic stress disorder (PTSD) by psychiatrists authorised under the TGA’s Authorised Prescriber scheme; other uses remain Schedule 9 and restricted to approved clinical research. The TGA requires HREC approval and strict importation/manufacturing controls; access is tightly constrained and must occur in supervised clinical settings with trained personnel. # #

Reimbursement/access notes: MDMA is not a routinely PBS‑reimbursed medicine; the TGA decision established a legal medical pathway but did not create an automatic public subsidy. Early rollouts have been clinician‑led and usually privately funded or delivered within research/compassionate programs; patients should expect significant out‑of‑pocket costs unless a future PBS listing or specific public funding stream is created. The TGA has emphasised slow, staged implementation and the need for psychiatrist training and supply‑chain authorisations before broader availability. #

Regulatory status and indication: Esketamine nasal spray (marketed as Spravato®) is an approved registered medicine with the Therapeutic Goods Administration for treatment‑resistant major depressive disorder in adults (to be initiated with a newly‑started oral antidepressant). The TGA’s product page records the approval (Decision date 5 March 2021; registration 9 March 2021) and the registered therapeutic indication. #

Reimbursement and access: Spravato® has been evaluated through Australia’s PBS processes and has been listed on the Pharmaceutical Benefits Scheme effective 1 May 2025 (authority required criteria apply for induction and continuing treatment). PBS listing means the pharmaceutical cost of the registered Spravato product is subsidised for patients who meet the PBAC/PBS criteria, but delivery still requires clinic infrastructure, supervised administration and authority approvals; patients may still face additional administration and supervision fees and travel/care costs. Authorisation and prescribing requirements are subject to the PBS authority rules (online PBS Authorities or telephone), and prescribers must comply with induction/continuation criteria set by PBAC/Services Australia. # #

Regional/territorial nuance applicable to Norfolk Island: Norfolk Island health services were assimilated into Australian Commonwealth health arrangements from 1 July 2016 such that Medicare and the PBS extend to island residents; therefore the PBS listing and authority processes that apply in mainland Australia extend to Norfolk Island residents (subject to local service availability and the logistics of certified treatment centres). Practical access for island residents will depend on whether an appropriately certified clinic or service is available on‑island or whether patients must travel to mainland Australia for supervised administration; travel and clinic costs remain relevant out‑of‑pocket considerations. # #

Legal/regulatory framework and clinical use: Ketamine (the racemate) is a legally authorised medicine in Australia for anaesthesia and certain approved indications; however, its use for psychiatric indications (for example, depression, TRD, or PTSD) is generally off‑label. Australian clinics and hospitals—primarily private specialist clinics and some hospital services—offer intravenous or intramuscular ketamine infusion therapy for psychiatric and chronic pain indications under off‑label prescribing frameworks, with clinicians relying on clinical judgment and informed consent. The TGA has not registered ketamine specifically for psychiatric indications, so these treatments operate under standard off‑label prescribing rules and relevant state/territory controlled‑drug regulations. # #

Reimbursement and access: Off‑label ketamine infusions are typically provided in private specialist clinics and are not routinely PBS‑subsidised for psychiatric indications; Medicare rebates do not normally cover the drug or private clinic administration costs for off‑label psychiatric use, so patients usually pay substantial out‑of‑pocket fees. In hospital settings where ketamine is used for anaesthesia or for approved indications, normal hospital funding and Medicare/PBS arrangements apply. For Norfolk Island residents, clinical access depends on local service availability—most specialised ketamine infusion services are on mainland Australia, so island residents generally must travel for treatment and bear travel and service costs. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT is listed as a prohibited Schedule 9 substance in the Australian Poisons Standard except where specifically authorised for research or under tightly controlled exemptions; possession, manufacture or supply outside authorised pathways is illegal. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. In Australia 5‑MeO‑DMT is treated as a prohibited Schedule 9 substance under the Poisons Standard (access limited to approved research or special licences). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is effectively prohibited for general clinical use in Australia and is only accessible through authorised research or special permits. (No routine medical/reimbursement pathway exists.)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT as an active constituent, they are treated as prohibited (Schedule 9) except under specific research exemptions or authorised licences. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are controlled in Australia and are Schedule 9 unless used in approved research or under specific authority. (There is no routine medical licence or reimbursement route.)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family of phenethylamine psychedelics are prohibited and are addressed under Schedule 9 restrictions; access is limited to authorised research. (No medical prescribing or reimbursement pathway.)